Similar articles for PMID: 31014050

Year	Number of Results
2006	1
2007	2
2008	1
2009	1
2010	1
2011	3
2012	1
2013	3
2014	4
2015	4
2016	14
2017	15
2018	14
2019	17
2020	19
2021	19
2022	6
2023	6
2024	0

1

[Mechanism of MALAT1 induced osimertinib resistance in HCC827 lung cancer cells].

Kang XH, Gao YY, Wang Y, Cui YH, Zhao KL, Kou WZ, Miao ZH, Cao F, Gong YB. Kang XH, et al. Zhonghua Zhong Liu Za Zhi. 2019 Apr 23;41(4):257-262. doi: 10.3760/cma.j.issn.0253-3766.2019.04.004. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31014050 Chinese.

2

[Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells].

Kang XH, Wang K, Wang Y, Zhao HK, Zhang J, Zhao KL, Miao ZH, Xu ZY, Cao F, Gong YB. Kang XH, et al. Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):210-215. doi: 10.3760/cma.j.cn112152-20190322-00186. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32252199 Chinese.

3

Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.

Tang ZH, Su MX, Guo X, Jiang XM, Jia L, Chen X, Lu JJ. Tang ZH, et al. Anticancer Agents Med Chem. 2018;18(4):550-555. doi: 10.2174/1871520617666170719155517. Anticancer Agents Med Chem. 2018. PMID: 28730963

4

[The role and mechanism of 2-deoxyglucose in reversing osimertinib-acquired resistance of non-small cell lung cancer cell line].

Hao S, Lu CH, Lin CC, Chen HY, Li L, Wang YB, Feng MX, He Y. Hao S, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2019 Mar 12;42(3):198-205. doi: 10.3760/cma.j.issn.1001-0939.2019.03.010. Zhonghua Jie He He Hu Xi Za Zhi. 2019. PMID: 30845397 Chinese.

5

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L. Wu S, et al. Mol Cancer. 2021 Jan 18;20(1):17. doi: 10.1186/s12943-021-01307-9. Mol Cancer. 2021. PMID: 33461557 Free PMC article.

6

Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.

Hisakane K, Seike M, Sugano T, Yoshikawa A, Matsuda K, Takano N, Takahashi S, Noro R, Gemma A. Hisakane K, et al. Thorac Cancer. 2021 Jun;12(11):1690-1698. doi: 10.1111/1759-7714.13943. Epub 2021 May 3. Thorac Cancer. 2021. PMID: 33939301 Free PMC article.

7

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.

Li Y, Zang H, Qian G, Owonikoko TK, Ramalingam SR, Sun SY. Li Y, et al. Cancer. 2020 Mar 15;126(6):1339-1350. doi: 10.1002/cncr.32655. Epub 2019 Dec 10. Cancer. 2020. PMID: 31821539 Free PMC article.

8

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

La Monica S, Minari R, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Galetti M, Digiacomo G, Riccardi F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x. Target Oncol. 2019. PMID: 31502118

9

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE. Frogne T, et al. Breast Cancer Res Treat. 2009 Mar;114(2):263-75. doi: 10.1007/s10549-008-0011-8. Epub 2008 Apr 14. Breast Cancer Res Treat. 2009. PMID: 18409071 Free PMC article.

10

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.

La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x. J Exp Clin Cancer Res. 2019. PMID: 31138260 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

118 results

Results by year